Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVITALISE Study
2025-522060-32-00Phase 2Authorised
- Sponsor
- CorFlow Therapeutics
- Start
- Jul 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 4
01
Overview
Phase 2, randomised trial in acute ST-segment elevation myocardial infarction (STEMI) comparing Intracoronary tirofiban, Intracoronary adenosine and Control / standard of care (3 arms). Primary endpoint: Absolute change in left ventricular ejection fraction. Planned start Jul 2026; status: authorised.
02
Drugs
tirofibanadenosine
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on 2025-522060-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522060-32-00.